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Curcumin Supplementation for Relief of Pain Associated with Osteoarthritis
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Abstract:
List of Abbreviations
NSAID
Nonsteroidal Anti-inflammatory drug
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Objective: To determine if curcumin supplementation compared to nonsteroidal antiinflammatory drugs (NSAIDs), placebo, and rescue medications is an effective treatment of
arthritic symptoms in males and females between the ages of 50 and 80 with a diagnosis of
osteoarthritis.
Design: Systematic Literature Review  
Methods: Searches were done in PubMed, Google Scholar, and Scopus utilizing the terms
“turmeric”, “curcumin”, “osteoarthritis”, “NSAIDs”, “ibuprofen”, and “placebo.” The following
limits were applied: excluded if compared greater than two remedies for treatment of
osteoarthritis or if turmeric was used as an “add-on” for treatment. Articles were included if they
only dealt with human subjects, were published in 2014 or later, and were full-text.
Results: A randomized control trial by Kuptniratsaikul, V. et al concluded that curcumin was as
efficacious as ibuprofen in reducing pain and improving function associated with Osteoarthritis
(OA) with the benefit that curcumin resulted in less gastrointestinal complaints. Srivastave, S. et
al concluded that curcumin can be used with diclofenac to provide relief in patients with knee
OA. The results demonstrated that patients in the curcumin and diclofenac group had
improvement in all three measures of the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) score when compared to patients in the placebo group. Panahi
Y. et al study showed a statistical significant improvement in measures of the WOMAC score in
the curcumin group while the placebo group showed no change in WOMAC parameters. The
curcumin group also had significant reduction in Visual Analogue Scale (VAS) and Lequesne
Pain and Function Index (LPFI) scores compared to placebo.
Conclusion: Curcumin may provide relief of osteoarthritic symptoms as demonstrated by
subjective measures of pain and objective measures of inflammation. Additionally, curcumin has
a strong safety profile, a low potential for toxicity, and few adverse side effects those of which
include gastrointestinal symptoms such as diarrhea and flatulence. Further research is needed to
investigate the relationship between curcumin and the impact on osteoarthritic symptoms

independent of NSAIDs. Additionally, population based studies are needed to see if the results of
a small sample size can be applied to the general population.

Introduction:	
  
	
  
Osteoarthritis (OA) is a degenerative joint disease characterized by joint pain, stiffness,
and restricted movement and is a leading cause of chronic disability in adults. Also called
degenerative joint disease, OA is characterized by sclerosis, osteophytosis, and joint space
narrowing. Weight bearing joints are frequently impacted and lead to increased disability and
impaired functioning of daily living activities (6). Commonly affected joints include the hands,
hips, knees and shoulders. A study conducted in 2005 estimated that over 27 million Americans
live with OA representing nearly 10% of the US population (1). Two major risk factors for the
development of OA include age and obesity. According to one study, the lifetime risk of
developing symptomatic knee arthritis was one in two people will develop symptomatic knee
arthritis by the age of 85 and two thirds of obese individuals will also develop OA (1). Despite
the prevalence and the impact on daily living, there are limited treatment options for OA.
The development of osteoarthritis is multifactorial, and the pathogenesis is complex. OA
is characterized by inflammation at the molecular level rather than the cellular level. The
development of OA involves the production of pro-inflammatory mediators and alterations in the
synovium and soft tissue of joints. When individuals are affected with OA, the body produces
pro-inflammatory mediators, including cytokines that stimulate the production of proteolytic
enzymes leading to breakdown of the articular cartilage. The synovium is also affected which
contributes to the development of pain and swelling. Over time, with increased breakdown of
the cartilage, the pain and inflammation worsens. Due to this effect, patients may experience
pain that worsens with activity and improves with rest.
Current treatment modalities for osteoarthritis are centered on symptom management
which encompass lifestyle changes such as weight loss, pharmacological treatment, and surgical
intervention. Treatment for OA targets relief of symptoms with the use of nonsteroidal antiinflammatory agents (NSAIDs), opioid analgesics, and intraarticular injections. Although
research has investigated the development of disease modifying drugs for the treatment of OA,
currently there is no FDA approved pharmacological treatment designed to change the
progression of the disease (3).
While NSAIDs remain the agent of choice for pain management in OA, long term use of
NSAIDs is associated with several adverse side effects, including gastrointestinal, renal, and
cardiovascular symptoms. This has led to an increased interest in herbal supplements for the
treatment of OA including curcumin. Curcumin is a yellow substance that comes from the
rhizomes of Cercuma Longa, otherwise known as turmeric (4). Although curcumin was
discovered in 1748, its first documented use in humans was not until 1937 when a paper was
published demonstrating the effect of curcumin in treating cholecystitis. Since then, further
studies have demonstrated that curcumin is safe, tolerable, and nontoxic in humans (5). Later
research has found curcumin to have anti-inflammatory and antioxidant properties, and it is
capable of inhibiting some of the pro-inflammatory mediators frequently seen in the
development of OA.

To date there is limited research on the effects of curcumin on symptom relief for
osteoarthritis; however, the research may suggest curcumin to have the same effect as NSAIDs
with the addition of limited gastrointestinal side effects. Therefore, the present study sought to
evaluate the effectiveness of curcumin in relieving symptoms of OA in males and females
between the ages of 50 and 80 when compared with placebo and NSAIDs.
	
  
	
  
Methods
An initial search of PubMed, Google Scholar, and Scopus was performed in September
2017 using the search terms “turmeric”, “curcumin”, “osteoarthritis”, “NSAIDs”, “ibuprofen”,
and “placebo” yielding 32 results (See Figure 1). Duplicate articles were removed, and the
articles were further searched and only included if they were randomized control trials published
in 2013 or later with full text articles available. This narrowed the results to 12 articles. The 12
full-text articles were assessed for eligibility and were excluded if they compared greater than
two remedies for treatment of osteoarthritis or if curcumin was used as an “add-on” for
treatment, yielding eight articles. Individual articles were reviewed, and three randomized
control trials were chosen as they were the only three comparing curcumin to a different
treatment options for osteoarthritis.

Figure 1. PRISMA flow diagram summarizing the article search process.
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Results:
Study #1
Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with
knee osteoarthritis: a multicenter study. Kuptniratsaikul, V. et al 2014
Objective:
This randomized control trial’s goal was to determine the efficacy and safety of curcumin
in pain reduction and functional improvement compared with ibuprofen in patients with
osteoarthritis.
Study Design:
Participants were recruited from eight tertiary hospitals in Thailand from July 2010 to
March 2012. Eligibility requirements included being a primary knee osteoarthritis patient
according to the American Rheumatism Association criteria and having a numerical score of
knee pain of ≥ 5 out of 10 and age ≥ 50 years. Patients were excluded if they had abnormal liver
function or renal function, history of peptic ulcer, allergy to curcumin or ibuprofen, or were
unable to walk. All inclusion and exclusion criteria is summarized in Table 1. All participants
received a knee x-ray to indicate severity of OA according to the Kellgren-Lawrence criteria, a
method of classifying the severity of knee osteoarthritis using a 0-4 scale depicted in Table 2 (6).
Table 1. Patient Inclusion and Exclusion Criteria; Kuptniratsaikul, V. et al 2014
Inclusion Criteria
Primary knee osteoarthritis patients according to American Rheumatism Association criteria
Numerical score of knee pain at least 5 out of 10
Age at least 50 years old
Exclusion Criteria
Abnormal liver or renal function
History of peptic ulcers
Allergy to curcumin or ibuprofen
Unable to walk

Table 2. Kellgren/Lawrence Osteoarthritis grading
Grade Classification
Grade 0 no radiographic features of OA are present
Grade 1 doubtful joint space narrowing (JSN) and possible osteophytic lipping
Grade 2 definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph
Grade 3 multiple osteophytes, definite JSN, sclerosis, possible bony deformity
Grade 4 large osteophytes, marked JSN, severe sclerosis and definite bony deformity
Subjects were randomized by computer to receive either 1,200 mg/day of ibuprofen or
1,500 mg/day of curcumin. Patients took two capsules after meals three times a day for four
weeks and were not allowed to take other medications during the study. Outcomes were
measured at week 2 and week 4 by the same assessor. Outcomes measured included the Western
Ontaria and McMaster Universities Osteoarthritis Index (WOMAC) and a 6-minute walk
distance. WOMAC is a widely used standardized questionnaire used to evaluate the condition of
patients with osteoarthritis of the knee and hip. WOMAC is broken down into 3 subscales; pain,
stiffness, and function, each on a scale from 0-10, the higher the score the worse off (7).
Adverse events were also compared between the two groups. Further, compliance of treatment
was assessed using pill count at each visit. At the end of the study, patient’s global assessment
and satisfaction was evaluated.
The final sample size included 331 patients; 160 ibuprofen and 171 curcumin
participants. The mean score of WOMAC and the 6-minute walk distance at week 4 were
compared between groups using analysis of covariance and the unpaired t-test. The adverse
events and satisfaction levels were analyzed using chi-square and the compliance of the drug
intake was compared using the t-test for equality.
Study Results:
The primary outcome focused on for this study was the WOMAC scores and the 6minute walk test. Eligible treatment group distribution is shown in table 3. The baseline
characteristics of participants were no different between the two randomized groups.
Table 3. Distribution of patients randomized to the treatment groups; Kuptniratsaikul, V. et al
2014
Patients
Initial
Withdrawal Week 2
Withdrawal Week 4
Completed study

Curcumin
185
3
11
171

Ibuprofen
182
8
14
160

Group comparison of the WOMAC scores showed statistically significant improvement
from baseline, however, the between-group comparison showed no difference in WOMAC
scores showing that the curcumin group was non-inferior to the ibuprofen group. Concerning the

effectiveness of curcumin, the primary outcomes of WOMAC and the 6-minute walk were
compared at week 4. The total WOMAC score for the curcumin was 3.36 while the ibuprofen
group total was 3.23. Broken down by section WOMAC pain subscale was a 3.25 for curcumin
versus 3.17 for ibuprofen. The WOMAC stiffness subscale was 3.28 for curcumin and 3.16 for
ibuprofen, and WOMAC function was 3.41 for curcumin compared to 3.26 ibuprofen. The 6minute walk in meters was 345.43 for the curcumin group compared to 347.99 for the ibuprofen
group. In summary, both the ibuprofen and the curcumin group showed improvement from
baseline. The WOMAC total score, pain, and functional ratings were equivocal between the two
groups. However, the curcumin group had greater reductions in the WOMAC stiffness scale
compared to the ibuprofen group which trended towards statistical significance (P value= 0.060).
Additionally, the number of patients that reported abdominal discomfort was significantly higher
in the ibuprofen group compared to the curcumin group (P value= 0.046) (see Table 4).
Table 4. Mean and SD for WOMAC and 6-minute walk distance at week 4 in ibuprofen and
curcumin groups; Kuptniratsaikul, V. et al 2014
Mean score at week 4
WOMAC score total
WOMAC pain
subscale
WOMAC stiffness
subscale
WOMAC function
subscale
6-minute walk
(meters)

Ibuprofen (n = 160) Curcumin (n = 171)
3.23 ± 1.97
3.36 ± 2.04
3.17 ± 1.98
3.25 ± 2.11

0.010
0.018

P-value

3.16 ± 2.36

3.28 ± 2.38

0.060

3.26 ± 2.05

3.41 ± 2.09

0.010

347.99 ± 86.60

345.43 ± 91.66

0.320

Secondary outcomes showed that overall there was no difference between adverse effects
between the groups, 35.7% in ibuprofen and 29.7% in the curcumin group, P = 0.222. Common
adverse effects included dyspepsia, abdominal pain/distension, nausea, loose stool, and pitting
edema. The rate of abdominal pain/distension was significantly lower in the curcumin group at
10.8% than in the ibuprofen group at 18.1%. Rates of dyspepsia, nausea, and pitting edema were
higher in the ibuprofen group compared to the curcumin group. Only the symptom of loose stool
was higher in the curcumin group 11.9% compared to 8.8% in the ibuprofen group (see Table 5).

Table 5. Adverse events occurring during study compared between two groups; Kuptniratsaikul,
V. et al 2014
Adverse events
Ibuprofen (n = 182)
Percentage of patients
35.7%
with adverse event
Abdominal
18.1%
pain/distension
Dyspepsia
15.9%
Nausea
8.2%
Loose stool
8.8%
Melena
1.1%
Pitting edema
7.1%

Curcumin (n = 185)
29.7%

P-value
0.222

10.8%

0.046*

11.4%
4.9%
11.9%
0%
3.8%

0.201
0.191
0.330
0.245
0.156

In addition, there was no statistical difference in drug compliance between the groups,
93.8% compliance in the ibuprofen group and 92.6% in the curcumin group; p-value 2.202. The
patient’s global assessment and satisfaction at week 4 also showed no difference between groups,
however, 96% and 97% of subjects in the ibuprofen and curcumin groups respectively, were
satisfied with the treatment. Further 63.8% and 64.3% respectively rated themselves as
improved (Table 6).
Table 6. Percentage of patient’s global assessment and satisfaction at week 4; Kuptniratsaikul,
V. et al 2014
Variables
Global assessment
Improved
Indifferent
Deteriorated
Satisfaction index
Satisfied
Indifferent
Unsatisfied

Ibuprofen (n=160)

Curcumin (n=171)

63.8%
32.5%
3.7%

64.3%
33.9%
1.8%

95.6%
4.4%
0.0%

97.1%
2.3%
0.6%

P-value
0.665

0.707

Based on all of the results stated above, Kuptniratsaikul concluded that curcumin is as
effective as ibuprofen for the treatment of knee osteoarthritis. The side effect profile was similar
but with fewer gastrointestinal adverse effects in the curcumin group.
	
  
Study Critique:
A strength of this article was the fact that it is a double-blind randomized controlled trial.
Further, strict inclusion and exclusion criteria were used to avoid confounding variables.
Examples of this include defining osteoarthritis according to the American Rheumatism

Association criteria and not including patients with co-morbid conditions such as renal and liver
disease. Both medications were manufactured by the Department of Pharmacy, Siriraj Hospital,
Bangkok, Thailand, in the form of a capsule, to make them identical in appearance. The
treatment codes were further kept by a pharmacist who was not involved in the study process.
An additional strength of this study was the large sample size, with a total of 331 participants
completing the study. Most other articles comparing curcumin had sample sizes much smaller,
typically with twenty to fifty patients total.
One drawback to this study was the use of multiple subjective results. These included the
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), adverse events
reported, as well as global assessment and overall satisfaction. The only objective data measured
in this study was the 6-minute walk test. Another limitation to the study was the short duration
at only 4 weeks. The short duration of the study may have skewed the results, thus resulting in
no statistical significance overall.
Another consideration when evaluating this article is when it comes to comparing the
patient population in Thailand to the population in the United States. Although the study was
completed in Thailand, the results can still be applied to a United States population. This is
because osteoarthritis is a degenerative joint disease which can affect anyone regardless of where
they live. There are different degrees of severity of OA, however, this is true regardless of what
country a person lives in. Further, the strict inclusion and exclusion criteria of this study, which
were according to the American Rheumatism Association, makes the study easily replicable in
any country.

Study #2
Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of
knee: a four-month, double-blind, randomized, placebo-controlled trial. Srivastava, S et al.
2016.
Objective:
This double-blind randomized placebo-controlled clinical trials primary goal was to
observe the effect of curcumin on clinical improvement in patients with knee osteoarthritis
(KOA) as assessed by the Visual Analog Scale (VAS) and the Western Ontario and McMaster
Universities Osteoarthritis index (WOMAC).
Study Design:
The study was conducted at King George’s Medical University in Lucknow, India.
Criteria for establishing a patient suffering from KOA were according to the guidelines proposed
by The American College of Rheumatology. Further, participants were included if they were
between the ages of 40-80. Radiographic osteoarthritis of the knee was classified according to
the Kellgren-Lawrence grading scale (see Table 2). Participants were excluded if they were less
than 40 years old or more than 80, if they suffered from rheumatoid arthritis, diabetes mellitus,

renal insufficiency, hepatic disease, cardiovascular disease, gout, were pregnant, or with any
other systemic disease. Inclusion and exclusion criteria is summarized in Table 7.
Table 7. Patient Inclusion and Exclusion Criteria; Srivastave, S. et al 2016.
Inclusion Criteria
Primary knee osteoarthritis patients according to American Rheumatism Association criteria
Age 40-80
Exclusion Criteria
Rheumatoid arthritis
Diabetes mellitus
Renal insufficiency
Hepatic disease
Cardiovascular disease
Gout
Pregnancy
Other systemic diseases
Participants were assigned by computerized randomization to receive either 500 mg of
curcumin and 50 mg/day of diclofenac or 500 mg placebo capsules along with 50 mg/day
diclofenac. The final sample size was 133 patients including 66 in the curcumin group and 67 in
the placebo group. Outcomes were measured on days 0, 60, and 120. Measurements included
the VAS, WOMAC, and biochemical markers including: Reactive Oxygen Species (ROS),
serum IL-1Beta, and serum MDA. The VAS is a subjective measurement, with use of a
horizontal line which contains word descriptions at each end, ranging from 0-10 representing
pain level. Zero indicates no pain and 10 indicates unbearable pain. The patient marks one of the
following options: no pain, mild pain, moderate pain, or severe pain. ROS and MDA are
biomarkers of oxidative stress and serum IL-1Beta is a marker of inflammation.
Results were analyzed using the chi-square test to compare categorical variables, the
unpaired t-test to compare discrete variables, and a paired t-test to compare mean change in
discrete variables from day 0 to 60, day 60 to 120, and day 0 to 120.
Study Results:
Outcomes focused on for this study included the VAS, WOMAC, and biochemical
markers ROS, MDA, and IL-1Beta. Eligible participant breakdown throughout the study is
summarized in table 8.

Table 8. Study participants; Srivastave, S. et al 2016.
Participants
Initial
Lost to follow-up after 60
days
Lost to follow-up after 120
days
Completed Study

Curcumin
78
7

Placebo
82
8

5

7

66

67

Group comparison of the visual analog scale (VAS) showed statistical significance (Pvalue <0.05) on Day 60 and Day 120 with scores being lower amongst the curcumin group. The
VAS score for curcumin at day 60 was 4.96 while the placebo group was 6.00. At day 120 the
VAS for the curcumin group was 4.03 and the placebo 5.11. Further, statistical significance was
seen amongst the WOMAC subcategories of pain and patient function between the two groups
for follow-up day 60 and day 120. In regards to pain, at day 60, the curcumin group was at 11.19
and the placebo group 12.05. At day 120, curcumin group was at 9.48 and the placebo group at
10.16. For patient function, at day 60 curcumin was 41.28 and placebo was 45.11, whereas, at
day 120, curcumin was 32.14 and placebo at 33.88 (see table 9).
Table 9. Effect of treatment on VAS and WOMAC scores between groups; Srivastave, S. et al
2016.
Parameters
VAS Score
Day 0
Day 60
Day 120
WOMAC Score
Pain
Day 0
Day 60
Day 120
Stiffness
Day 0
Day 60
Day 120
Patient Function
Day 0
Day 60
Day 120

Curcumin

Placebo

P value

7.94 ± 0.13
4.96±0.07
4.03±0.08

7.66±0.14
6.00±0.11
5.11±0.14

0.15
0.0001*
0.0001*

15.10±0.31
11.19±0.26
9.48±0.17

15.29±0.26
12.05±0.21
10.16±0.16

0.64
0.01*
0.06*

5.55±0.21
4.51±0.21
4.08±0.17

5.31±0.12
4.70±0.23
4.16±0.18

0.53
0.54
0.73

54.03±0.68
41.28±0.51
32.14±0.40

50.99±0.68
45.11±0.37
33.88±0.50

0.008
0.0001*
0.008*

Biochemical outcomes, which is objective data, also showed statistical significance
amongst groups for ROS at days 0. 60, and 120 respectively, and for MDA at day 60 and 120.
The ROS for the curcumin group at day 0 was 3798 MFI compared to 2584 MFI for the placebo
group. For day 60, curcumin was 2553 MFI and the placebo 2144 MFI, and for day 120 the
curcumin was 1200 MFI and the placebo group 2197 MFI. For MDA at day 60 the curcumin
group was 3.85 nmol/ml and the placebo 5.00 nmol/ml. At day 120, the curcumin group MDA
was 3.96 nmol/ml and the placebo group 4.91 nmol/ml (see Table 10).
Table 10. Effect of treatment on biochemical parameters between the study groups; Srivastave, S.
et al 2016.
Parameters
IL-1b (pg/ml)
Day 0
Day 60
Day 120
ROS (MFI)
Day 0
Day 60
Day 120
MDA (nmol/ml)
Day 0
Day 60
Day 120

Curcumin

Placebo

P value

126.4 ±19.94
65.61 ±21.59
21.11 ±1.176

131.5 ±19.79
74.83 ±22.31
35.82 ±7.53

0.85
0.76
0.55

3798 ±1507.77
2553 ±775.67
1200 ±864.08

2584 ±671.74
2144 ±1275.97
2197 ±1378.90

0.001*
0.001*
0.0001*

5.02 ±0.16
3.85 ±0.12
3.69 ±0.12

5.15 ±0.14
5.00 ±0.11
4.91 ±0.11

0.57
0.0001*
0.0001*

Overall clinical assessment amongst participants showed statistically significant
improvement in presence of joint crepitation, joint stiffness, and joint effusion between the two
groups. There was an overall reduction of 60% of participants with presence of joint crepitation
for the curcumin group and 20% reduction for the placebo group. A 64% overall reduction was
seen in the curcumin group in regards to presence of joint stiffness and a 31.8% reduction for the
placebo group. Lastly, an overall reduction of 75.8% was seen in the curcumin group for joint
effusion presence and 37% for the placebo group (see Table 11).
Table 11. Clinical assessment parameters between the two groups; Srivastave, S. et al 2016.
Parameters
Reduction of joint
crepitation
Reduction of joint
stiffness
Reduction of joint
effusion

Curcumin
60%

Placebo group
20%

P value
0.001*

64%

31.8%

0.027*

75.8%

37%

0.003*

In conclusion this study showed that adjuvant therapy curcumin along with diclofenac
produces overall significant improvement in patients with knee osteoarthritis. Thus, it is
proposed that patients with KOA should be given curcumin as soon as the diagnosis is made to
help improve outcomes.
Study Critique:
One strength of this article is that it was performed as a double blind randomized control
trial which helps eliminate some potential confounding variables. Additionally, its use of
objective data including measurements of reactive oxygen species (ROS), IL-1Beta, and MDA,
which are biomarkers of inflammation and oxidative stress provide a more accurate account of
efficacy. Objective data provides concrete evidence of improvements of knee osteoarthritis
among the curcumin treatment group. Another strength of the study is the use of multiple
follow-up days, measuring all data at day 60 and then again at day 120. This allows for
continuous monitoring to see if improvements are shown throughout the four months and not just
at the end of the study.
One of the drawbacks of this study was the small sample size. In the end, only 133
participants completed the study, 66 in the curcumin group and 67 in the placebo group. This is
not a very large number, and significance could have changed if the sample size was larger.
Another drawback of the study was the fact that both groups used diclofenac, an NSAID used to
treat knee osteoarthritis. Because of the combination of treatment, in the end, it remains
unknown how much the curcumin really benefited the treatment group versus if the diclofenac
was what benefited the group.
Another consideration is if this study can be applied to the United States as it was
performed in India. However, osteoarthritis is a degenerative joint disease that can affect any
person regardless of where they live in the country. Further, the inclusion and exclusion criteria
for this study were set according to the American College of Rheumatology, and due to this
standard criteria, the study can easily be replicated and repeated in any country.

Study #3
Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double-Blind PlaceboControlled Trial. Panahi, Y et. al, 2014.
Objective:
This double-blinded randomized placebo-controlled study sought to determine the
clinical efficacy of curcumin in reducing clinical symptoms of knee osteoarthritis as assessed by
the McMaster Universities Osteoarthritis Index (WOMAC) score, Lequesne’s pain functional

index (LPFI), and visual analogue score (VAS). The aim of this pilot study was to determine the
efficacy of curcumin in alleviating OA symptoms when co-administered with the brand name
Bioperine, also known as the generic agent, piperine, an extract that enhances the absorption of
curcumin.
Study Design:
The study included patients with a diagnosis of knee OA who were referred to the
Baqiyatallah University Clinic in Tehran, Iran during 2011 and 2012. Participants were permitted
to participate if they had primary knee OA with mild to moderate severity, as determined by
radiological and clinical criteria. The radiological criteria is defined by the American College of
Rheumatology, and the clinical criteria was determined by patients scoring on the VAS score.
Participants had to score at least 40 mm on a 100 mm VAS score rating when assessed for the
degree of pain on active movement. The study had several exclusion criteria which are listed in
table 12.
Table 12. Patient Inclusion and Exclusion Criteria; Panahi Y. et al 2014.
Inclusion Criteria
Primary knee osteoarthritis with mild to moderate severity as defined by the American College
of Rheumatology and the Visual Analogue Scale score of at least 40 mm on a 100 mm scale
Bilateral OA
Age less than 80 years old
Exclusion Criteria
Allergy to curcuminoids or other herbal medications
Candidates for surgical joint replacement or any other surgical treatment
OA secondary to trauma
Rheumatoid arthritis
Hemophilia
Malabsorption disorders
Active or generalized inflammatory disorders (erythrocyte sedimentation rate (ESR) greater
than 20)
Heart, renal or liver disease
Corticosteroid use over 10 mg/day in the preceding 3 months
History of psychological disorders
Intra-articular injections administered within the preceding 3 months

Participants were randomly assigned using a 1:1 ratio scheme in consecutive order to
receive either curcumin 1500 mg/day or placebo for 6 weeks. Patients in the curcumin group
were instructed to take three 500 mg tablets each day. The curcumin capsules each contained 5
mg Bioperine to enhance the absorption of the curcumin; the placebo tablets contained starch.
During each week of the trial, regular consumption of the tablets was monitored. Both the

curcumin group and the placebo group were allowed to take naproxen when they experienced
intolerable discomfort. The final sample size that completed the trial included 19 participants in
the curcumin group and 21 in the placebo group.
Outcome measurements were assessed using the WOMAC, VAS and the LPFI. The
WOMAC index was used to determine the severity of OA symptoms and included 5 items
relating to pain, 2 items relating to stiffness, and 17 items to assess physical functioning. Each
item is then rated on a scale of 0 to 4, with a total score of 0-20 for pain, 0-8 for stiffness, and 068 for physical functioning.
This study determined the severity of pain by using the VAS scores collected from
participants. The VAS score ranges from a score of zero, indicating no pain at all, to a score of
100 which signifies unbearable pain. The VAS scores are collected by having the patient mark
on a horizontal line the number that correlates to his or her level of knee pain severity.
The Lequesne’s pain functional index (LPFI) looks at pain, maximum distance walked,
and activities of daily living (ADL). The pain and ADL scores range from 0 to 8 with zero
representing no pain or no functional limitations and 8 representing maximum level of
impairment. The maximum distance walked ranges from 0 to 6, with zero representing unlimited
ability to walk and 6 signifying severe limitations with less than 100 meters of walking distance.
Further, the LPFI score is increased by one point if the patient uses one crutch and two points if
the patient uses two crutches. The LPFI scores range from 0 to 24, with higher scores
representing a decreased health and more severe impairment.
The statistical analysis was carried out by computers, and each parameter was assessed at
baseline and at the end of the trial using a paired samples T-test. The differences in magnitude
were assessed using independent t-tests. A p-value less than 0.05 was considered statistically
significant in this study.
Study Results:
Outcomes in this study focused on WOMAC scores, LPFI, and VAS scores among
curcumin and placebo groups. The baseline characteristics between the two groups were matched
for age, gender, BMI and mean WOMAC, LPFI, and VAS scores.
Participants in the curcumin group had a statistically significant reduction in mean
WOMAC scores with respect to global score, physical function, and stiffness at the end of the
trial when compared to individuals in the placebo group. The WOMAC scores for individuals in
the placebo group had no change in the score, pain, or physical function. However, participants
in the placebo group had a statistically significant decrease in the stiffness subscale. When the
two groups were compared, curcumin showed a decrease in WOMAC scores for measures of
global assessment, pain, and physical functioning. However, no statistical significance was found
between curcumin and placebo for a change in stiffness. Refer to table 14 for comparison among
groups.
When comparing LPFI and VAS scores among the two groups a statistically significant
reduction in scores was seen in the curcumin group compared to the placebo. Additionally, 84%
of subjects in the curcumin group reported a reduction in the use of naproxen compared to
individuals in the placebo group (P value <0.001). However, reduction in the use of naproxen
was based upon patients own recordings of usage. Patients receiving curcumin reported using
250 to 500 mg of naproxen compared to individuals in the placebo group reporting use of 500 to
750 mg of naproxen.

Table 13 shows the breakdown of individuals among groups. The researchers determined
that the loss of follow-up was not due to adverse effects associated with curcumin
supplementation, with four patients in the placebo group reporting mild gastrointestinal
symptoms and seven in the curcumin group which was not shown to be statistically significant.

Table 13. Study participants; Panahi, Y. 2014
Participants
Initial
Lost to follow-up
Completed Study

Curcumin
27
8
19

Placebo
26
5
21

Table 14. Effect of treatment on WOMAC scores between groups; Panahi, Y. et al 2014.
Parameters
WOMAC Score
Pain
Before
treatment
After
treatment
Stiffness
Before
treatment
After treatment
Patient function
Before
Treatment
After
treatment
Global score
Before
Treatment
After
Treatment

Curcumin

Placebo

P-value within
group

P-value
between
groups

9.9± 4.1

10.5±4

<0.001*

<0.001*

6.1±2.9

9.4±3.4

0.025*

<0.001*

1.05±1.8

1.7±1.7

0.043*

0.912

0.15±0.5

0.76±0.9

0.009*

0.912

31.8±14

32.4± 12.8

<0.001*

<0.001*

18.7±10.3

30.4±9.4

42.4±18.3

44.6±17.3

<0.001*

0.001*

25.0±13

40.6±12.6

Study Critique:
One of the strengths of this study was that it is a double-blinded randomized placebocontrolled study. Further, if participants did not complete the study or were noncompliant, they

were not included in the overall results of the study. Another strength is the addition of Bioperine
to the curcumin group which allowed for greater absorption of the compound and may have
produced more efficacious results. The addition of Bioperine has been shown to increase blood
concentrations of curcumin in the intestinal tissue and enhance permeability. In previous studies,
curcumin has had limited efficacy due to its poor systemic absorption when taken by itself.
Another strength of this study is that it is a randomized control trial which helps control
confounding variables that otherwise could skew the results.
The major limitation of this study was the small sample size. The study included a total
of 40 patients that completed the trial which may make it difficult to generalize the findings to
the larger population as a whole. Despite the small sample size, researchers were still able to
demonstrate statistical significance for the effect of curcumin on improving WOMAC, VAS, and
LPFI scores. A second limitation of this study was that participants were only supplemented with
curcumin for a duration of 6 weeks. Considering that OA is a chronic condition, if patients
benefited from use of curcumin, it is likely that he or she would supplement indefinitely. This
makes it difficult to determine the long-term efficacy of curcumin from a trial lasting such a
short duration. The third limitation of this study was that only patients with mild to moderate OA
were allowed to participate. The trial does not address if patients suffering from severe OA are
likely to benefit from curcumin supplementation.
Another limitation is that the study did not clearly define what intolerable pain was, and
therefore, it was up to each patient to determine if they needed naproxen. The study also relied
on self -reported data of naproxen use. It is possible patients forgot to keep track of each time
naproxen was used which could have significantly altered the results.
Additionally, this study was performed in Iran and not the United States. However,
osteoarthritis is a degenerative joint disease that can be seen in any country. Therefore, this
study can still be applied to the United States.
Discussion:
To date, there is limited research on the effects of curcumin on symptom relief for
osteoarthritis. All three of the articles reviewed concluded that use of curcumin is as effective as
other currently used treatments such as NSAIDs. Additionally, curcumin has the added benefit
of fewer gastrointestinal adverse effects. Side effects of curcumin supplementation include
gastrointestinal upset such as diarrhea, flatulence, and abdominal bloating. Patients taking
warfarin or other blood thinners should proceed with caution as long term use can thin the blood.
An overview of the three studies including demographics, treatment, tests used, conclusion, and
limitations can be seen in Table 15.
The Kuptniratsaikul, V. et al 2014 study concluded that curcumin is an efficacious and
safe alternative to the use of ibuprofen for the treatment of osteoarthritis. Further, in regards to
safety concerns, curcumin was been shown to have a better safety profile than ibuprofen in terms
of abdominal pain and distension. They found that curcumin can be provided at 2,000 mg/d for
6 weeks or an even higher dose of up to 8,000 mg/d for 3 months without any serious adverse
effects.
The Srivastave, S. et al 2016 study concluded that adjuvant therapy of curcumin along
with diclofenac produces significant improvement in patients with knee arthritis, and therefore,
curcumin should be given as soon as the diagnosis is made. Further, NSAIDs, if required, may

be given for a short period, but curcumin may be prescribed for long durations without fear of
gastrointestinal or kidney adverse effects. The Srivastave, S. et al study was the only study
included in this review that used biochemical measures including ROS, serum IL-1Beta, and
serum MDA. This provided concrete results to support the effectiveness of curcumin.
The Panahi, Y. et al 2014 study found curcumin to be effective in alleviating the
symptoms and improving care of patients with osteoarthritis. However, they concluded that
these benefits should be exercised with caution due to limitations and further research needed.
The Panahi, Y. et al study suggests that due to the positive results in this trial, future larger-scale
trials should explore if curcumin can be used as a therapeutic regimen of patients suffering from
knee osteoarthritis.
Due to the lack of research on curcumin, all three research articles used in this review
used different variables making comparisons difficult. The Kuptniratsaikul, V. et al study
compared curcumin to ibuprofen. The Sirvastave, S. et al study compared curcumin and
diclofenac versus placebo and diclofenac. The Panahi, Y. et al study compared curcumin with
the addition of Bioperine to placebo. A limitation seen in all three studies was that they allowed
the use of rescue drugs as needed for severe flare up of osteoarthritic symptoms. Due to this fact,
it is difficult to assess whether the curcumin alone had positive effects in relieving OA symptoms
versus if it was simply the use of NSAIDs or the combination of the two bringing about the
effect. Another limitation of all three trials is the short duration of treatment with curcumin. The
longest duration of treatment amongst all three studies reviewed was only three months. This
made it challenging to assess benefits of curcumin.
Due to the limitations mentioned above, more research is needed on the use of curcumin
alone without the use of rescue medications, and longer trials are needed to assess benefits.
Conclusion
Does curcumin supplementation when compared to NSAIDs, placebo, and rescue medications
provide greater relief of arthritic symptoms in males and females between the ages of 40 and 80
with a prior diagnosis of osteoarthritis?
Based on the results of these small double-blinded trials, curcumin may be an effective
alternative to NSAIDs in controlling pain associated with osteoarthritis symptoms with
minimized gastrointestinal side effects. Therefore, curcumin may be a reasonable alternative to
patient who cannot tolerate NSAIDs due to the GI and cardiovascular adverse effects. However,
due to the lack of research to date, additional studies on the use of curcumin in the treatment of
OA are needed before a definitive recommendation can be made to the general population for its
usefulness in pain relief in patients with OA. Future studies should include larger population
based studies with longer duration of supplementation to better assess the general population as a
whole and the effectiveness of curcumin. Further, additional studies would provide more
accurate results if the use of rescue medications was limited. However, it may be unrealistic and
unethical to ask subjects to limit the use of pain relievers in an effort to obtain clinical data.
	
  
	
  
	
  
	
  

	
  
	
  
	
  
	
  
Table 15. Overview of Studies

Treatment

Kuptniratsaikul, V. et
al 2014
331
At least 50 yo
Males and Females
8 tertiary hospitals in
Thailand July 2010March 2012
Curcumin vs. Ibuprofen

Study length
Follow-ups
Tests
administered

4 weeks
At 2 weeks, 4 weeks
WOMAC
6-minute walk distance

Conclusion

Curcumin is as effective
as ibuprofen for the
treatment of knee
osteoarthritis with fewer
gastrointestinal adverse
effects in the curcumin
group.

Sample size
Patient age
Gender
Location

Limitations

	
  

-Short duration
-Rescue med Toradol
used for exacerbations
-Results mostly
subjective in nature

Srivastave, S. et al
2016
133
40-80 yo
Males and females
King George’s Medical
University in Lucknow,
India
Curcumin and
Diclofenac vs. Placebo
and Diclofenac
3 months
At day 0, 60, 120
VAS
WOMAC
Biochemical markers:
ROS, serum IL-1Beta,
serum MDA
Adjuvant therapy of
curcumin along with
diclofenac produces
overall significant
improvement in patients
of knee OA.
NSAIDs, if required,
may be given for a short
period but curcumin
may be prescribed for
long durations, without
fear of damaging the GI
or kidneys.
-Small sample size
-Use of adjuvant
diclofenac

Panahi, Y. et al 2014
40
Less than 80 yo
Males and Females
Baqiyatallah
University Clinic in
Tehran, Iraq 2011-2012
Curcumin vs. Placebo
6 weeks
None
VAS
WOMAC
LPFI
Curcumin and the
addition of Bioperine is
an effective and safe
alternative treatment
for osteoarthritis.

-Small sample size
-Results were all
subjective
-Rescue med Naproxen
used for exacerbations
-Only treated mild to
moderate OA patients
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